Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focusing on kidney disease, announced its participation in the 2nd Annual HCW Bioconnect Investor Conference in New York on May 20, 2024. CEO John Butler will engage in a fireside chat at 3:00 p.m. ET. The presentation will be available via webcast on Akebia's investor relations website for 30 days post-conference.
- Participation in a high-profile investor conference enhances visibility.
- Presentation by CEO John Butler could bolster investor confidence.
- Webcast availability for 30 days extends reach to a broader audience.
- No new financial or clinical data disclosed during the announcement.
- Potential dilution risks if no substantial updates are provided at the event.
- Lack of specific business development updates may disappoint investors looking for concrete progress.
The 2nd Annual HCW Bioconnect Investor Conference will take place in
A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-2nd-annual-hcw-bioconnect-investor-conference-302144820.html
SOURCE Akebia Therapeutics, Inc.
FAQ
When is Akebia Therapeutics participating in the HCW Bioconnect Investor Conference?
What time will Akebia Therapeutics present at the HCW Bioconnect Investor Conference?
How can I access the Akebia Therapeutics presentation at the HCW Bioconnect Investor Conference?
What is the stock symbol for Akebia Therapeutics?